DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive Capital

AI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of their AI drug design engine and advance therapeutic candidates. The investment underscores strong confidence in their innovative approach to tackling diseases.